Free tool
FAERS Monitor: Marcaine Hydrochloride W/ Epinephrine Preservative Free
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016964 or its brand name (Marcaine Hydrochloride W/ Epinephrine Preservative Free, Bupivacaine Hydrochloride, Epinephrine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
4,747
Serious
2,732
58% of reports
Hospitalization
1,140
Death reported
318
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,603
- anaesthetic complication278
- off label use246
- pain228
- hypoaesthesia213
- maternal exposure during pregnancy211
- hypotension199
- headache181
- dyspnoea169
- dizziness154
- nausea149
- condition aggravated144
- fatigue144
- hypertension143
- vomiting137
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 77 |
| 2006 | 97 |
| 2007 | 65 |
| 2008 | 85 |
| 2009 | 124 |
| 2010 | 104 |
| 2011 | 101 |
| 2012 | 94 |
| 2013 | 94 |
| 2014 | 112 |
| 2015 | 191 |
| 2016 | 619 |
| 2017 | 390 |
| 2018 | 241 |
| 2019 | 242 |
| 2020 | 242 |
| 2021 | 200 |
| 2022 | 407 |
| 2023 | 256 |
| 2024 | 331 |
| 2025 | 336 |
| 2026 | 247 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,412 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaesthetic complicationSignal | 278 | 511.5 | 453.3 | 126,552 |
| maternal exposure during pregnancySignal | 211 | 10.5 | 9.2 | 1,810 |
| hypoaesthesiaSignal | 213 | 6.3 | 5.5 | 952 |
| drug ineffectiveSignal | 1,603 | 5.4 | 5.2 | 6,110 |
| hypotensionSignal | 199 | 4.4 | 3.8 | 524 |
| hypertensionSignal | 143 | 3.0 | 2.5 | 190 |
| condition aggravatedSignal | 144 | 2.1 | 1.8 | 83 |
| pain | 228 | 1.6 | 1.4 | 59 |
| dizziness | 154 | 1.4 | 1.2 | 15 |
| dyspnoea | 169 | 1.3 | 1.1 | 13 |
| vomiting | 137 | 1.3 | 1.1 | 9 |
| headache | 181 | 1.3 | 1.1 | 11 |
| off label use | 246 | 1.2 | 1.1 | 12 |
| nausea | 149 | 0.8 | 0.7 | 5 |
| fatigue | 144 | 0.8 | 0.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.